Delivery Order SPE2DB20D3103-SPE2DB25FQ4T8
Award Date 9/25/25
Potential Completion Date 9/26/25
Potential Value $25K
Federal Agency
Awardee
Ultimate Awardee
Not listed PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Defense Logistics Agency awarded a delivery order valued at $15,015.87 to AmerisourceBergen Drug Corp for Ruxience 500 mg/50 mL vials on August 7, 2025, with an ultimate completion date of August 8, 2025. This competitively awarded, firm fixed-price contract represents a non-set-aside procurement and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. Ruxience is a biosimilar to rituximab used in treating various cancers and autoimmune conditions,...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded AmerisourceBergen Drug Corp a delivery order valued at $11,951.84 for RUXIENCE 500 mg/50 ml vials on August 19, 2025, with completion scheduled for August 20, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the company's corporate office location in Conshohocken, Pennsylvania. RUXIENCE is a biosimilar to rituximab used in the treatment of various cancers...
- The Defense Logistics Agency awarded a delivery order valued at $14,773.25 to AmerisourceBergen Drug Corp for the supply of Ruxience 500 mg/50 mL vials. This competitively awarded, firm fixed-price delivery order was issued on August 21, 2025, with an ultimate completion date of August 22, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Ruxience is a biosimilar medication used in cancer treatment and other therapeutic applications, representing part of the...
- The Defense Logistics Agency awarded a delivery order valued at $13,014.23 to AmerisourceBergen Drug Corp for Ruxience 500 mg/50 mL vials on May 12, 2025, with a completion date of May 13, 2025. This firm fixed-price delivery order, issued without a set-aside designation, will be performed at the contractor's location in Conshohocken, Pennsylvania. Ruxience is a biosimilar medication used in oncology and immunology treatments, reflecting the agency's ongoing need to supply critical...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Ruxience 500 mg/50 mL vials, valued at $13,824.28 under a firm fixed-price arrangement. This non-set-aside delivery order was awarded on July 8, 2025, with an ultimate completion date of July 9, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Ruxience is a biosimilar monoclonal antibody used in the treatment of various cancers and...
- The Defense Logistics Agency awarded a $10,908.55 firm fixed price delivery order to Amerisourcebergen Drug Corporation for Ruxience 500 MG/50 ML vials. Under this order, Amerisourcebergen will deliver 50 mL vials of Ruxience, a biosimilar to Rituxan used to treat certain types of cancer and autoimmune disorders, to a facility in Conshohocken, Pennsylvania by August 31, 2023. As a major component of the Department of Defense that manages global logistics operations for the military services, the...
- The Defense Logistics Agency awarded a $39,673.94 delivery order to AmerisourceBergen Drug Corp for the supply of Ruxience 500 mg/50 ml vials on August 29, 2025, with an ultimate completion date of September 2, 2025. This competitively awarded, firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $1 billion through December 2026. The place of performance is located in...
- The Defense Logistics Agency awarded a $6,413.75 firm fixed price delivery order to Amerisourcebergen Drug Corp for Ruxience 500 MG/50 ML vials. As the prime contractor, Amerisourcebergen Drug Corp will deliver 50 ML vials of the biosimilar drug Ruxience to its Conshohocken, Pennsylvania location by August 10, 2023 to support the Defense Logistics Agency's medical supply needs. The delivery order was issued under an existing Amerisourcebergen Corporation indefinite-delivery/indefinite-quantity...
- This delivery order awards AmerisourceBergen Drug Corp a firm fixed-price contract valued at $1,467.66 for the supply of Ruxience 500 mg/50 ml vials. The contract was awarded competitively without a set-aside designation on April 28, 2025, with an ultimate completion date of April 29, 2025. The Defense Logistics Agency (DLA), through its federal medical procurement operations, is funding this award. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania,...
- AmerisourceBergen Drug Corp received a $21,846.24 firm fixed-price delivery order from the Defense Logistics Agency (DLA) for 500 mg/50 mL vials of Ruxience, a biosimilar medication, with an ultimate completion date of September 11, 2025. This non-set-aside award was competitively issued and will be performed at the company's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with...